Matthew Daley
Concepts (493)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccination | 112 | 2026 | 1426 | 10.090 |
Why?
| | Vaccines | 42 | 2026 | 388 | 7.770 |
Why?
| | Vaccination Coverage | 23 | 2026 | 102 | 6.640 |
Why?
| | Influenza Vaccines | 45 | 2026 | 534 | 5.340 |
Why?
| | Immunization Schedule | 35 | 2026 | 186 | 4.620 |
Why?
| | Influenza, Human | 31 | 2025 | 624 | 3.780 |
Why?
| | Immunization Programs | 20 | 2024 | 193 | 2.990 |
Why?
| | Papillomavirus Vaccines | 15 | 2022 | 296 | 2.500 |
Why?
| | Immunization | 23 | 2024 | 375 | 2.390 |
Why?
| | Advisory Committees | 20 | 2024 | 229 | 2.190 |
Why?
| | Papillomavirus Infections | 10 | 2022 | 344 | 2.170 |
Why?
| | Electronic Health Records | 29 | 2025 | 1196 | 2.090 |
Why?
| | Health Knowledge, Attitudes, Practice | 18 | 2025 | 1419 | 2.040 |
Why?
| | Child, Preschool | 87 | 2026 | 11853 | 2.000 |
Why?
| | Adverse Drug Reaction Reporting Systems | 14 | 2022 | 81 | 1.970 |
Why?
| | Infant | 86 | 2026 | 10077 | 1.860 |
Why?
| | United States | 101 | 2026 | 16098 | 1.680 |
Why?
| | Practice Patterns, Physicians' | 18 | 2024 | 1371 | 1.590 |
Why?
| | Eczema | 3 | 2022 | 66 | 1.560 |
Why?
| | Hypertension | 10 | 2026 | 1273 | 1.550 |
Why?
| | School Health Services | 11 | 2018 | 221 | 1.520 |
Why?
| | Child | 105 | 2026 | 22707 | 1.510 |
Why?
| | Humans | 249 | 2026 | 145474 | 1.510 |
Why?
| | Patient Acceptance of Health Care | 13 | 2022 | 881 | 1.440 |
Why?
| | Social Media | 4 | 2021 | 166 | 1.440 |
Why?
| | Pediatric Obesity | 8 | 2025 | 638 | 1.420 |
Why?
| | Parents | 16 | 2023 | 1403 | 1.420 |
Why?
| | Adolescent | 95 | 2026 | 22529 | 1.390 |
Why?
| | Female | 168 | 2026 | 78844 | 1.390 |
Why?
| | Body Mass Index | 15 | 2026 | 2445 | 1.390 |
Why?
| | Reminder Systems | 7 | 2016 | 140 | 1.390 |
Why?
| | Male | 143 | 2026 | 72842 | 1.240 |
Why?
| | Pregnancy Complications, Infectious | 7 | 2025 | 440 | 1.220 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 10 | 2022 | 261 | 1.140 |
Why?
| | Internet | 6 | 2024 | 689 | 1.140 |
Why?
| | Rural Population | 5 | 2025 | 659 | 1.130 |
Why?
| | Urban Population | 3 | 2025 | 493 | 1.110 |
Why?
| | Diphtheria-Tetanus-acellular Pertussis Vaccines | 11 | 2026 | 91 | 1.100 |
Why?
| | Pneumococcal Vaccines | 10 | 2025 | 129 | 1.090 |
Why?
| | Colorado | 35 | 2026 | 4553 | 1.070 |
Why?
| | Antihypertensive Agents | 4 | 2026 | 519 | 1.060 |
Why?
| | Information Dissemination | 2 | 2020 | 224 | 0.980 |
Why?
| | Anti-Bacterial Agents | 6 | 2024 | 1923 | 0.970 |
Why?
| | Rotavirus Vaccines | 8 | 2026 | 39 | 0.970 |
Why?
| | Libraries, Medical | 2 | 2024 | 11 | 0.960 |
Why?
| | Practice Guidelines as Topic | 15 | 2024 | 1581 | 0.940 |
Why?
| | Adult | 90 | 2026 | 40777 | 0.930 |
Why?
| | Young Adult | 58 | 2026 | 14218 | 0.920 |
Why?
| | Pediatrics | 17 | 2020 | 1121 | 0.910 |
Why?
| | Measles | 3 | 2022 | 46 | 0.900 |
Why?
| | Pandemics | 9 | 2025 | 1707 | 0.890 |
Why?
| | Product Surveillance, Postmarketing | 6 | 2017 | 74 | 0.870 |
Why?
| | Transportation | 1 | 2025 | 57 | 0.850 |
Why?
| | Retrospective Studies | 44 | 2026 | 17291 | 0.840 |
Why?
| | Asthma | 5 | 2022 | 1797 | 0.830 |
Why?
| | Thrombocytopenia | 3 | 2022 | 204 | 0.780 |
Why?
| | Data Collection | 16 | 2017 | 640 | 0.780 |
Why?
| | Ambulatory Care | 5 | 2024 | 609 | 0.770 |
Why?
| | Weight Gain | 6 | 2026 | 561 | 0.760 |
Why?
| | Egg Hypersensitivity | 1 | 2022 | 28 | 0.740 |
Why?
| | Guideline Adherence | 8 | 2024 | 586 | 0.740 |
Why?
| | Hepatitis B Vaccines | 4 | 2026 | 43 | 0.730 |
Why?
| | Community-Acquired Infections | 1 | 2024 | 177 | 0.710 |
Why?
| | Abortion, Spontaneous | 4 | 2025 | 118 | 0.700 |
Why?
| | Pregnancy | 25 | 2026 | 7202 | 0.700 |
Why?
| | Attitude of Health Personnel | 13 | 2020 | 1193 | 0.690 |
Why?
| | Data Mining | 3 | 2022 | 113 | 0.680 |
Why?
| | Blood Pressure | 5 | 2024 | 1779 | 0.670 |
Why?
| | Surveys and Questionnaires | 17 | 2025 | 6066 | 0.660 |
Why?
| | Whooping Cough | 6 | 2023 | 55 | 0.650 |
Why?
| | Peanut Hypersensitivity | 1 | 2022 | 143 | 0.650 |
Why?
| | Vaccination Refusal | 2 | 2018 | 61 | 0.650 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 3 | 2018 | 28 | 0.640 |
Why?
| | Anaphylaxis | 3 | 2019 | 102 | 0.640 |
Why?
| | Seasons | 11 | 2025 | 538 | 0.640 |
Why?
| | Obesity | 7 | 2022 | 3116 | 0.630 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2020 | 16 | 0.620 |
Why?
| | Reimbursement Mechanisms | 3 | 2018 | 79 | 0.620 |
Why?
| | Education, Medical, Continuing | 1 | 2021 | 133 | 0.610 |
Why?
| | Geographic Information Systems | 1 | 2020 | 45 | 0.610 |
Why?
| | Syncope | 2 | 2017 | 56 | 0.600 |
Why?
| | Weight Loss | 6 | 2025 | 858 | 0.600 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 2 | 2014 | 429 | 0.590 |
Why?
| | Family Practice | 8 | 2015 | 407 | 0.590 |
Why?
| | Pneumococcal Infections | 3 | 2025 | 103 | 0.590 |
Why?
| | Mothers | 3 | 2025 | 765 | 0.580 |
Why?
| | Information Storage and Retrieval | 2 | 2020 | 123 | 0.580 |
Why?
| | Haemophilus Vaccines | 4 | 2025 | 29 | 0.560 |
Why?
| | Middle Aged | 60 | 2026 | 36215 | 0.560 |
Why?
| | Vaccines, Attenuated | 7 | 2023 | 129 | 0.550 |
Why?
| | Pneumonia | 1 | 2024 | 636 | 0.540 |
Why?
| | Infant, Newborn | 19 | 2026 | 6447 | 0.540 |
Why?
| | Delivery of Health Care | 5 | 2019 | 946 | 0.540 |
Why?
| | Population Surveillance | 7 | 2020 | 484 | 0.540 |
Why?
| | Hepatitis B | 3 | 2026 | 66 | 0.540 |
Why?
| | Montana | 3 | 2023 | 18 | 0.530 |
Why?
| | Cohort Studies | 28 | 2025 | 6013 | 0.530 |
Why?
| | Urinary Tract Infections | 1 | 2020 | 210 | 0.520 |
Why?
| | Incidence | 17 | 2021 | 2923 | 0.520 |
Why?
| | Drug Hypersensitivity | 2 | 2019 | 90 | 0.510 |
Why?
| | Cross-Sectional Studies | 16 | 2025 | 5904 | 0.500 |
Why?
| | Poliovirus Vaccine, Inactivated | 2 | 2014 | 27 | 0.500 |
Why?
| | Rotavirus Infections | 4 | 2026 | 37 | 0.500 |
Why?
| | Learning | 1 | 2021 | 443 | 0.490 |
Why?
| | Healthcare Disparities | 1 | 2023 | 735 | 0.490 |
Why?
| | Self Report | 4 | 2025 | 870 | 0.480 |
Why?
| | Prehypertension | 2 | 2013 | 27 | 0.480 |
Why?
| | Databases, Pharmaceutical | 1 | 2016 | 4 | 0.480 |
Why?
| | Age Factors | 13 | 2026 | 3342 | 0.470 |
Why?
| | Aluminum | 3 | 2022 | 43 | 0.470 |
Why?
| | Primary Health Care | 11 | 2024 | 1735 | 0.470 |
Why?
| | Treatment Refusal | 3 | 2013 | 98 | 0.470 |
Why?
| | Disease Outbreaks | 3 | 2011 | 419 | 0.460 |
Why?
| | Computers, Handheld | 1 | 2016 | 26 | 0.460 |
Why?
| | Professional-Family Relations | 2 | 2015 | 153 | 0.460 |
Why?
| | Guillain-Barre Syndrome | 4 | 2026 | 23 | 0.450 |
Why?
| | Quality Assurance, Health Care | 3 | 2014 | 342 | 0.440 |
Why?
| | Databases, Factual | 9 | 2025 | 1490 | 0.440 |
Why?
| | Consumer Health Information | 1 | 2015 | 49 | 0.430 |
Why?
| | Bias | 7 | 2021 | 197 | 0.430 |
Why?
| | Risk Assessment | 15 | 2022 | 3747 | 0.420 |
Why?
| | Safety | 5 | 2018 | 358 | 0.420 |
Why?
| | Prevalence | 10 | 2025 | 2865 | 0.410 |
Why?
| | Hepatitis A Vaccines | 3 | 2026 | 19 | 0.410 |
Why?
| | Deductibles and Coinsurance | 1 | 2014 | 12 | 0.410 |
Why?
| | Overweight | 5 | 2020 | 614 | 0.410 |
Why?
| | Hepatitis A | 2 | 2026 | 25 | 0.390 |
Why?
| | Dental Hygienists | 1 | 2013 | 14 | 0.380 |
Why?
| | Decision Making | 3 | 2018 | 977 | 0.380 |
Why?
| | Health Care Surveys | 8 | 2013 | 536 | 0.370 |
Why?
| | Drug Approval | 6 | 2021 | 93 | 0.370 |
Why?
| | Chronic Disease | 5 | 2022 | 1808 | 0.360 |
Why?
| | Central Nervous System Stimulants | 1 | 2014 | 185 | 0.360 |
Why?
| | Interrupted Time Series Analysis | 2 | 2024 | 75 | 0.360 |
Why?
| | Measles-Mumps-Rubella Vaccine | 5 | 2022 | 48 | 0.350 |
Why?
| | Patient Compliance | 1 | 2016 | 587 | 0.350 |
Why?
| | Trust | 1 | 2013 | 155 | 0.340 |
Why?
| | Vaccines, Inactivated | 6 | 2020 | 70 | 0.340 |
Why?
| | Attitude to Health | 4 | 2018 | 430 | 0.340 |
Why?
| | Aged | 29 | 2026 | 26153 | 0.340 |
Why?
| | Immunization, Secondary | 6 | 2025 | 92 | 0.340 |
Why?
| | Myocarditis | 2 | 2022 | 102 | 0.330 |
Why?
| | Community Health Services | 1 | 2013 | 231 | 0.330 |
Why?
| | Licensure, Medical | 1 | 2010 | 17 | 0.320 |
Why?
| | Premature Birth | 3 | 2024 | 388 | 0.310 |
Why?
| | Risk Factors | 15 | 2025 | 10885 | 0.310 |
Why?
| | Herpes Zoster Vaccine | 4 | 2023 | 154 | 0.310 |
Why?
| | Vaccines, Synthetic | 4 | 2026 | 137 | 0.310 |
Why?
| | Multivariate Analysis | 5 | 2013 | 1547 | 0.310 |
Why?
| | Patient-Centered Care | 2 | 2013 | 547 | 0.300 |
Why?
| | Haemophilus Infections | 2 | 2025 | 45 | 0.300 |
Why?
| | Insurance, Health | 4 | 2018 | 310 | 0.300 |
Why?
| | Lisinopril | 2 | 2026 | 15 | 0.300 |
Why?
| | Phentermine | 2 | 2019 | 14 | 0.290 |
Why?
| | Infant Behavior | 1 | 2008 | 28 | 0.280 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 3 | 2018 | 13 | 0.280 |
Why?
| | Anti-Obesity Agents | 2 | 2019 | 67 | 0.280 |
Why?
| | Proportional Hazards Models | 7 | 2021 | 1327 | 0.270 |
Why?
| | Pregnancy Outcome | 4 | 2025 | 503 | 0.270 |
Why?
| | Natural Language Processing | 2 | 2019 | 106 | 0.270 |
Why?
| | Insurance, Health, Reimbursement | 3 | 2014 | 98 | 0.270 |
Why?
| | Mass Screening | 2 | 2014 | 1360 | 0.270 |
Why?
| | Hospitalization | 7 | 2026 | 2460 | 0.270 |
Why?
| | Heart Defects, Congenital | 3 | 2020 | 910 | 0.270 |
Why?
| | Risk | 6 | 2022 | 919 | 0.260 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 919 | 0.260 |
Why?
| | Logistic Models | 7 | 2019 | 2134 | 0.250 |
Why?
| | Firearms | 2 | 2024 | 436 | 0.250 |
Why?
| | Vaccines, Combined | 4 | 2023 | 49 | 0.250 |
Why?
| | Atenolol | 1 | 2026 | 8 | 0.240 |
Why?
| | Clonidine | 1 | 2026 | 33 | 0.240 |
Why?
| | Propranolol | 1 | 2026 | 44 | 0.240 |
Why?
| | Quetiapine Fumarate | 1 | 2026 | 26 | 0.240 |
Why?
| | Aripiprazole | 1 | 2026 | 20 | 0.240 |
Why?
| | Risperidone | 1 | 2026 | 30 | 0.240 |
Why?
| | Spironolactone | 1 | 2026 | 40 | 0.230 |
Why?
| | Stillbirth | 2 | 2024 | 81 | 0.230 |
Why?
| | Parent-Child Relations | 1 | 2008 | 271 | 0.230 |
Why?
| | Haemophilus influenzae type b | 1 | 2025 | 12 | 0.230 |
Why?
| | Meningococcal Vaccines | 4 | 2022 | 57 | 0.220 |
Why?
| | Attention | 1 | 2008 | 461 | 0.220 |
Why?
| | Cluster Analysis | 2 | 2023 | 500 | 0.220 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2025 | 39 | 0.220 |
Why?
| | Poisson Distribution | 5 | 2018 | 78 | 0.210 |
Why?
| | Case-Control Studies | 12 | 2025 | 3623 | 0.210 |
Why?
| | Travel | 2 | 2023 | 136 | 0.210 |
Why?
| | Fathers | 1 | 2025 | 53 | 0.210 |
Why?
| | Infant, Small for Gestational Age | 2 | 2024 | 118 | 0.210 |
Why?
| | Autism Spectrum Disorder | 2 | 2022 | 422 | 0.210 |
Why?
| | Physicians, Family | 3 | 2011 | 176 | 0.200 |
Why?
| | Registries | 5 | 2011 | 2406 | 0.200 |
Why?
| | Models, Theoretical | 2 | 2020 | 558 | 0.200 |
Why?
| | Pregnancy Trimester, First | 1 | 2024 | 139 | 0.200 |
Why?
| | Antipsychotic Agents | 1 | 2026 | 211 | 0.200 |
Why?
| | Health Policy | 2 | 2023 | 400 | 0.200 |
Why?
| | Epidural Neoplasms | 1 | 2003 | 1 | 0.200 |
Why?
| | International Classification of Diseases | 2 | 2020 | 150 | 0.200 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2025 | 139 | 0.200 |
Why?
| | Herpes Zoster | 2 | 2023 | 319 | 0.200 |
Why?
| | Seizures | 3 | 2018 | 483 | 0.190 |
Why?
| | Gastrointestinal Diseases | 3 | 2018 | 221 | 0.190 |
Why?
| | Depression, Postpartum | 1 | 2025 | 116 | 0.190 |
Why?
| | Tetanus | 1 | 2023 | 26 | 0.190 |
Why?
| | Regression Analysis | 3 | 2014 | 1001 | 0.190 |
Why?
| | Prospective Studies | 9 | 2023 | 8057 | 0.190 |
Why?
| | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2022 | 5 | 0.190 |
Why?
| | Anticonvulsants | 1 | 2025 | 246 | 0.190 |
Why?
| | Library Surveys | 1 | 2022 | 1 | 0.190 |
Why?
| | Cholera Vaccines | 1 | 2022 | 1 | 0.190 |
Why?
| | Typhoid-Paratyphoid Vaccines | 1 | 2022 | 5 | 0.190 |
Why?
| | Time Factors | 13 | 2022 | 7123 | 0.190 |
Why?
| | Cultural Diversity | 1 | 2024 | 83 | 0.190 |
Why?
| | Burkitt Lymphoma | 1 | 2003 | 61 | 0.190 |
Why?
| | Cholera | 1 | 2022 | 9 | 0.190 |
Why?
| | Checklist | 1 | 2024 | 110 | 0.190 |
Why?
| | Chorioamnionitis | 1 | 2023 | 50 | 0.190 |
Why?
| | Sentinel Surveillance | 2 | 2016 | 46 | 0.180 |
Why?
| | Urticaria | 1 | 2022 | 38 | 0.180 |
Why?
| | Chickenpox Vaccine | 4 | 2022 | 76 | 0.180 |
Why?
| | Health Planning Guidelines | 1 | 2022 | 24 | 0.180 |
Why?
| | Neoplasms | 1 | 2018 | 2906 | 0.180 |
Why?
| | Antidepressive Agents | 1 | 2024 | 242 | 0.180 |
Why?
| | Internal Medicine | 3 | 2010 | 279 | 0.180 |
Why?
| | Seizures, Febrile | 1 | 2022 | 23 | 0.180 |
Why?
| | Influenza A Virus, H1N1 Subtype | 3 | 2013 | 159 | 0.180 |
Why?
| | Exanthema | 1 | 2022 | 86 | 0.180 |
Why?
| | Antimicrobial Stewardship | 1 | 2024 | 130 | 0.180 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2022 | 94 | 0.170 |
Why?
| | Drug Prescriptions | 1 | 2024 | 288 | 0.170 |
Why?
| | Minnesota | 3 | 2017 | 168 | 0.170 |
Why?
| | Arachis | 1 | 2022 | 108 | 0.170 |
Why?
| | Rotavirus | 1 | 2021 | 21 | 0.170 |
Why?
| | Pharmacoepidemiology | 1 | 2021 | 23 | 0.170 |
Why?
| | United States Food and Drug Administration | 4 | 2024 | 208 | 0.170 |
Why?
| | Wounds, Gunshot | 1 | 2024 | 258 | 0.160 |
Why?
| | Epilepsy | 1 | 2025 | 390 | 0.160 |
Why?
| | Body Height | 1 | 2022 | 202 | 0.160 |
Why?
| | Papillomaviridae | 2 | 2018 | 116 | 0.160 |
Why?
| | Language | 1 | 2024 | 323 | 0.160 |
Why?
| | Outpatients | 1 | 2024 | 447 | 0.160 |
Why?
| | Managed Care Programs | 4 | 2015 | 140 | 0.160 |
Why?
| | Bursitis | 1 | 2020 | 9 | 0.160 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2014 | 268 | 0.160 |
Why?
| | Models, Statistical | 4 | 2023 | 671 | 0.160 |
Why?
| | Pyelonephritis | 1 | 2020 | 13 | 0.160 |
Why?
| | Antigens | 2 | 2021 | 348 | 0.160 |
Why?
| | Cystitis | 1 | 2020 | 24 | 0.160 |
Why?
| | Cephalexin | 1 | 2020 | 14 | 0.150 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2020 | 43 | 0.150 |
Why?
| | Immunologic Factors | 1 | 2022 | 260 | 0.150 |
Why?
| | Hepatitis A Virus, Human | 1 | 2019 | 2 | 0.150 |
Why?
| | Vaccine Potency | 1 | 2019 | 6 | 0.150 |
Why?
| | Appetite Depressants | 1 | 2019 | 19 | 0.150 |
Why?
| | Medical Record Linkage | 1 | 2020 | 68 | 0.150 |
Why?
| | Epidemiological Monitoring | 1 | 2019 | 69 | 0.150 |
Why?
| | Dermatitis, Atopic | 1 | 2022 | 322 | 0.150 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1323 | 0.150 |
Why?
| | Public Health | 2 | 2022 | 572 | 0.150 |
Why?
| | California | 2 | 2019 | 471 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2025 | 992 | 0.140 |
Why?
| | Environment | 1 | 2020 | 293 | 0.140 |
Why?
| | Intention | 1 | 2020 | 186 | 0.140 |
Why?
| | Sunburn | 1 | 2018 | 26 | 0.140 |
Why?
| | Nevus | 1 | 2018 | 26 | 0.140 |
Why?
| | Respiratory Tract Infections | 3 | 2026 | 396 | 0.140 |
Why?
| | Patient Participation | 2 | 2012 | 439 | 0.140 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2018 | 40 | 0.140 |
Why?
| | Condylomata Acuminata | 1 | 2018 | 7 | 0.140 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2930 | 0.140 |
Why?
| | Delivery of Health Care, Integrated | 3 | 2021 | 303 | 0.130 |
Why?
| | New Zealand | 1 | 2018 | 54 | 0.130 |
Why?
| | Longitudinal Studies | 2 | 2022 | 2953 | 0.130 |
Why?
| | Shoulder Joint | 1 | 2020 | 199 | 0.130 |
Why?
| | Biometry | 1 | 2018 | 66 | 0.130 |
Why?
| | Physicians | 4 | 2012 | 955 | 0.130 |
Why?
| | Rhinitis, Allergic | 1 | 2018 | 42 | 0.130 |
Why?
| | Odds Ratio | 6 | 2019 | 1082 | 0.130 |
Why?
| | Communicable Diseases | 1 | 2020 | 166 | 0.130 |
Why?
| | Aged, 80 and over | 9 | 2025 | 8333 | 0.130 |
Why?
| | Blood Pressure Determination | 2 | 2015 | 145 | 0.130 |
Why?
| | Parental Consent | 2 | 2014 | 25 | 0.130 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 69 | 0.130 |
Why?
| | Sex Factors | 3 | 2021 | 2105 | 0.130 |
Why?
| | Siblings | 1 | 2018 | 196 | 0.130 |
Why?
| | Family Health | 1 | 2018 | 191 | 0.130 |
Why?
| | Infant, Premature | 1 | 2022 | 619 | 0.130 |
Why?
| | Cost-Benefit Analysis | 3 | 2015 | 639 | 0.130 |
Why?
| | Body Weight | 2 | 2018 | 971 | 0.130 |
Why?
| | Australia | 1 | 2018 | 288 | 0.130 |
Why?
| | Thrombosis | 1 | 2021 | 400 | 0.130 |
Why?
| | Health Maintenance Organizations | 2 | 2014 | 105 | 0.130 |
Why?
| | Vaccines, Conjugate | 3 | 2022 | 59 | 0.120 |
Why?
| | United Kingdom | 1 | 2018 | 344 | 0.120 |
Why?
| | Diastole | 1 | 2017 | 146 | 0.120 |
Why?
| | Systole | 1 | 2017 | 181 | 0.120 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2021 | 364 | 0.120 |
Why?
| | Maternal Exposure | 1 | 2018 | 189 | 0.120 |
Why?
| | Diagnostic Errors | 1 | 2018 | 178 | 0.120 |
Why?
| | Health Services Research | 3 | 2022 | 391 | 0.120 |
Why?
| | Health Status Disparities | 1 | 2019 | 321 | 0.120 |
Why?
| | Follow-Up Studies | 6 | 2025 | 5423 | 0.120 |
Why?
| | Hypoglycemic Agents | 1 | 2025 | 1399 | 0.120 |
Why?
| | Ultraviolet Rays | 1 | 2018 | 384 | 0.120 |
Why?
| | Food Hypersensitivity | 1 | 2018 | 164 | 0.110 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2017 | 194 | 0.110 |
Why?
| | Cardiovascular Diseases | 2 | 2019 | 2187 | 0.110 |
Why?
| | Data Accuracy | 1 | 2016 | 65 | 0.110 |
Why?
| | Reproducibility of Results | 3 | 2019 | 3413 | 0.110 |
Why?
| | Quality Improvement | 1 | 2024 | 1295 | 0.110 |
Why?
| | Public Health Surveillance | 3 | 2020 | 83 | 0.110 |
Why?
| | Depression | 1 | 2025 | 1546 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 389 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 383 | 0.110 |
Why?
| | Pilot Projects | 2 | 2022 | 1891 | 0.110 |
Why?
| | Contraceptives, Oral | 1 | 2014 | 37 | 0.110 |
Why?
| | Social Welfare | 1 | 2014 | 27 | 0.110 |
Why?
| | Needs Assessment | 1 | 2017 | 402 | 0.100 |
Why?
| | Direct Service Costs | 1 | 2014 | 9 | 0.100 |
Why?
| | Program Evaluation | 1 | 2018 | 943 | 0.100 |
Why?
| | Adjuvants, Immunologic | 1 | 2015 | 243 | 0.100 |
Why?
| | Breast Feeding | 1 | 2018 | 446 | 0.100 |
Why?
| | Focus Groups | 2 | 2014 | 569 | 0.100 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2021 | 3922 | 0.100 |
Why?
| | Bacterial Capsules | 2 | 2025 | 33 | 0.100 |
Why?
| | Costs and Cost Analysis | 1 | 2014 | 221 | 0.100 |
Why?
| | Research Design | 4 | 2022 | 1137 | 0.090 |
Why?
| | Dyslipidemias | 1 | 2014 | 184 | 0.090 |
Why?
| | Health Promotion | 1 | 2019 | 775 | 0.090 |
Why?
| | Maternal Age | 2 | 2023 | 128 | 0.090 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2019 | 652 | 0.090 |
Why?
| | Computer Simulation | 2 | 2013 | 1003 | 0.090 |
Why?
| | Health Services | 1 | 2013 | 113 | 0.090 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 1 | 2012 | 18 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2015 | 740 | 0.090 |
Why?
| | Mass Vaccination | 1 | 2011 | 18 | 0.080 |
Why?
| | Skin Neoplasms | 1 | 2018 | 849 | 0.080 |
Why?
| | Venous Thromboembolism | 1 | 2015 | 328 | 0.080 |
Why?
| | Prescriptions | 2 | 2022 | 74 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2025 | 2588 | 0.080 |
Why?
| | Environmental Exposure | 1 | 2015 | 578 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2023 | 2803 | 0.080 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 1097 | 0.080 |
Why?
| | Physicians, Primary Care | 1 | 2013 | 208 | 0.080 |
Why?
| | Health Care Costs | 1 | 2014 | 425 | 0.080 |
Why?
| | Drug Recalls | 1 | 2010 | 3 | 0.080 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2010 | 47 | 0.080 |
Why?
| | Respiratory Syncytial Virus, Human | 2 | 2023 | 81 | 0.080 |
Why?
| | Medical Records Systems, Computerized | 1 | 2011 | 95 | 0.080 |
Why?
| | Medicare Part D | 1 | 2010 | 23 | 0.080 |
Why?
| | Polysaccharides, Bacterial | 1 | 2010 | 69 | 0.080 |
Why?
| | Haemophilus influenzae | 1 | 2010 | 67 | 0.080 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2010 | 62 | 0.080 |
Why?
| | Pertussis Vaccine | 1 | 2009 | 24 | 0.070 |
Why?
| | Chickenpox | 1 | 2010 | 84 | 0.070 |
Why?
| | Videotape Recording | 1 | 2008 | 37 | 0.070 |
Why?
| | Patient Education as Topic | 2 | 2011 | 777 | 0.070 |
Why?
| | Communication | 1 | 2015 | 975 | 0.070 |
Why?
| | Data Interpretation, Statistical | 2 | 2021 | 368 | 0.070 |
Why?
| | Autistic Disorder | 1 | 2011 | 219 | 0.070 |
Why?
| | Feasibility Studies | 1 | 2013 | 1111 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2020 | 2381 | 0.070 |
Why?
| | Massachusetts | 1 | 2008 | 180 | 0.070 |
Why?
| | Disease Susceptibility | 2 | 2020 | 344 | 0.070 |
Why?
| | Neuralgia, Postherpetic | 1 | 2008 | 40 | 0.070 |
Why?
| | Anemia, Sickle Cell | 1 | 2011 | 318 | 0.060 |
Why?
| | Confidence Intervals | 2 | 2021 | 330 | 0.060 |
Why?
| | Observational Studies as Topic | 2 | 2018 | 133 | 0.060 |
Why?
| | Postal Service | 2 | 2008 | 27 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1997 | 0.060 |
Why?
| | Risk-Taking | 1 | 2009 | 323 | 0.060 |
Why?
| | Pregnancy Trimester, Third | 1 | 2026 | 119 | 0.060 |
Why?
| | Carbamazepine | 1 | 2025 | 24 | 0.060 |
Why?
| | Metoprolol | 1 | 2025 | 26 | 0.060 |
Why?
| | Mortality | 2 | 2019 | 378 | 0.060 |
Why?
| | Valproic Acid | 1 | 2025 | 49 | 0.060 |
Why?
| | Health Surveys | 3 | 2017 | 518 | 0.060 |
Why?
| | Sulfonylurea Compounds | 1 | 2025 | 51 | 0.060 |
Why?
| | Triazines | 1 | 2025 | 49 | 0.060 |
Why?
| | Insulin, Long-Acting | 1 | 2025 | 65 | 0.060 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2025 | 46 | 0.060 |
Why?
| | Cause of Death | 2 | 2019 | 470 | 0.060 |
Why?
| | Urban Health | 1 | 2005 | 96 | 0.050 |
Why?
| | Fructose | 1 | 2025 | 132 | 0.050 |
Why?
| | Rural Health | 1 | 2005 | 87 | 0.050 |
Why?
| | Parenting | 1 | 2008 | 319 | 0.050 |
Why?
| | Duloxetine Hydrochloride | 1 | 2024 | 10 | 0.050 |
Why?
| | Probability | 1 | 2005 | 307 | 0.050 |
Why?
| | Citalopram | 1 | 2024 | 32 | 0.050 |
Why?
| | Safety-net Providers | 1 | 2025 | 130 | 0.050 |
Why?
| | Office Automation | 1 | 2004 | 5 | 0.050 |
Why?
| | Bupropion | 1 | 2024 | 48 | 0.050 |
Why?
| | Live Birth | 1 | 2024 | 81 | 0.050 |
Why?
| | Public Health Practice | 1 | 2004 | 63 | 0.050 |
Why?
| | Herpesvirus 3, Human | 2 | 2023 | 343 | 0.050 |
Why?
| | Toxoids | 1 | 2023 | 1 | 0.050 |
Why?
| | Epidural Space | 1 | 2003 | 17 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2025 | 184 | 0.050 |
Why?
| | Congenital Abnormalities | 1 | 2024 | 109 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 3193 | 0.050 |
Why?
| | Patient Selection | 1 | 2007 | 738 | 0.050 |
Why?
| | Spinal Cord Compression | 1 | 2003 | 24 | 0.050 |
Why?
| | Calcium Channel Blockers | 1 | 2024 | 166 | 0.050 |
Why?
| | Vibrio cholerae O1 | 1 | 2022 | 1 | 0.050 |
Why?
| | Patient Care | 1 | 2004 | 119 | 0.050 |
Why?
| | Travel-Related Illness | 1 | 2022 | 5 | 0.050 |
Why?
| | Antacids | 1 | 2022 | 16 | 0.050 |
Why?
| | Drug Utilization | 2 | 2013 | 168 | 0.050 |
Why?
| | Blood Group Antigens | 1 | 2022 | 15 | 0.050 |
Why?
| | Poverty Areas | 1 | 2002 | 43 | 0.050 |
Why?
| | Dehydration | 1 | 2022 | 58 | 0.050 |
Why?
| | Measles Vaccine | 1 | 2022 | 19 | 0.050 |
Why?
| | Family Characteristics | 1 | 2023 | 195 | 0.040 |
Why?
| | Information Systems | 1 | 2021 | 56 | 0.040 |
Why?
| | Metformin | 1 | 2025 | 329 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 428 | 0.040 |
Why?
| | Telephone | 1 | 2002 | 177 | 0.040 |
Why?
| | Safety-Based Drug Withdrawals | 1 | 2021 | 2 | 0.040 |
Why?
| | Algorithms | 2 | 2020 | 1845 | 0.040 |
Why?
| | Office Visits | 2 | 2015 | 92 | 0.040 |
Why?
| | Drug Labeling | 1 | 2021 | 37 | 0.040 |
Why?
| | Medication Adherence | 1 | 2025 | 540 | 0.040 |
Why?
| | Medicaid | 1 | 2025 | 467 | 0.040 |
Why?
| | Epidemiologic Research Design | 2 | 2013 | 29 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2009 | 1101 | 0.040 |
Why?
| | Deltoid Muscle | 1 | 2020 | 6 | 0.040 |
Why?
| | Treatment Outcome | 4 | 2019 | 11772 | 0.040 |
Why?
| | Fever | 1 | 2022 | 319 | 0.040 |
Why?
| | Insurance Claim Reporting | 1 | 2020 | 26 | 0.040 |
Why?
| | Injections, Intramuscular | 1 | 2020 | 146 | 0.040 |
Why?
| | Child Health Services | 1 | 2022 | 186 | 0.040 |
Why?
| | Morbidity | 1 | 2020 | 322 | 0.040 |
Why?
| | Epidemiologic Methods | 1 | 2019 | 91 | 0.040 |
Why?
| | Graphic Novels as Topic | 1 | 2019 | 1 | 0.040 |
Why?
| | Student Health Services | 1 | 2019 | 15 | 0.040 |
Why?
| | Water | 1 | 2022 | 445 | 0.040 |
Why?
| | Evidence-Based Practice | 1 | 2021 | 231 | 0.040 |
Why?
| | Orthomyxoviridae | 1 | 2019 | 40 | 0.040 |
Why?
| | Florida | 1 | 2019 | 117 | 0.040 |
Why?
| | Medical Informatics | 1 | 2019 | 99 | 0.040 |
Why?
| | History, 21st Century | 1 | 2019 | 222 | 0.040 |
Why?
| | Pancreatitis | 1 | 2019 | 146 | 0.030 |
Why?
| | Birth Weight | 1 | 2021 | 514 | 0.030 |
Why?
| | Gestational Age | 1 | 2021 | 987 | 0.030 |
Why?
| | Croup | 1 | 2018 | 19 | 0.030 |
Why?
| | Patient Safety | 1 | 2022 | 356 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2024 | 924 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2018 | 147 | 0.030 |
Why?
| | Appendicitis | 1 | 2019 | 150 | 0.030 |
Why?
| | Minority Groups | 1 | 2019 | 284 | 0.030 |
Why?
| | Linear Models | 1 | 2019 | 845 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 782 | 0.030 |
Why?
| | Respiratory Sounds | 1 | 2017 | 103 | 0.030 |
Why?
| | Universities | 1 | 2019 | 445 | 0.030 |
Why?
| | Prediabetic State | 1 | 2019 | 249 | 0.030 |
Why?
| | Social Class | 1 | 2018 | 264 | 0.030 |
Why?
| | Propensity Score | 1 | 2018 | 377 | 0.030 |
Why?
| | Government Programs | 1 | 2015 | 27 | 0.030 |
Why?
| | Otitis Media | 1 | 2018 | 182 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1747 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2121 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 2014 | 201 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2015 | 244 | 0.020 |
Why?
| | Off-Label Use | 1 | 2013 | 51 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 1963 | 0.020 |
Why?
| | Antigens, Viral | 1 | 2013 | 182 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2014 | 360 | 0.020 |
Why?
| | Quality Control | 1 | 2012 | 161 | 0.020 |
Why?
| | Tetanus Toxoid | 1 | 2012 | 34 | 0.020 |
Why?
| | Encephalitis | 1 | 2014 | 142 | 0.020 |
Why?
| | Triglycerides | 1 | 2014 | 520 | 0.020 |
Why?
| | Professional Practice Location | 1 | 2011 | 26 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4316 | 0.020 |
Why?
| | Bell Palsy | 1 | 2011 | 9 | 0.020 |
Why?
| | Physical Examination | 1 | 2013 | 243 | 0.020 |
Why?
| | Medically Uninsured | 1 | 2012 | 132 | 0.020 |
Why?
| | Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2010 | 13 | 0.020 |
Why?
| | Survival Rate | 1 | 2016 | 2090 | 0.020 |
Why?
| | Comorbidity | 1 | 2016 | 1661 | 0.020 |
Why?
| | Schools | 1 | 2014 | 448 | 0.020 |
Why?
| | Pharmaceutical Services | 1 | 2011 | 76 | 0.020 |
Why?
| | Income | 1 | 2012 | 202 | 0.020 |
Why?
| | Fees, Pharmaceutical | 1 | 2010 | 8 | 0.020 |
Why?
| | Job Satisfaction | 1 | 2011 | 237 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2011 | 462 | 0.020 |
Why?
| | Health Behavior | 1 | 2013 | 789 | 0.020 |
Why?
| | Health Care Rationing | 1 | 2007 | 56 | 0.020 |
Why?
| | Efficiency, Organizational | 1 | 2008 | 141 | 0.020 |
Why?
| | Demography | 1 | 2008 | 282 | 0.020 |
Why?
| | Intussusception | 1 | 2007 | 26 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2011 | 910 | 0.020 |
Why?
| | Mass Media | 1 | 2005 | 39 | 0.010 |
Why?
| | Perception | 1 | 2007 | 378 | 0.010 |
Why?
| | Policy Making | 1 | 2004 | 83 | 0.010 |
Why?
|
|
Daley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|